<DOC>
	<DOCNO>NCT00004038</DOCNO>
	<brief_summary>Phase I trial study effectiveness gene therapy plus chemotherapy treating patient breast cancer . Inserting p53 gene person 's cancer cell may improve body 's ability fight cancer make cancer sensitive chemotherapy . Combining chemotherapy gene therapy may kill tumor cell .</brief_summary>
	<brief_title>Gene Therapy Plus Chemotherapy Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect adenovirus p53 ( Ad-p53 ) chemotherapy-induced apoptosis lesion patient breast cancer . II . Determine p53 protein expression follow intralesional injection Ad-p53 immunohistochemistry reverse transcriptase polymerase chain reaction patient population . III . Determine time course magnitude development humoral antibody response adenoviral vector patient population . IV . Determine ability transfected p53 upregulate downstream signal important G1 arrest assay WAF1 mRNA apoptosis patient population . V. Determine toxicity side effect intralesional injection Ad-p53 give combination standard chemotherapy patient cutaneous subcutaneous metastatic breast cancer amenable injection biopsy . VI . Determine increase apoptosis induce Ad-53 compare baseline patient population . OUTLINE : Patients undergo biopsy one skin nodules prior treatment . Patients receive Ad-p53 gene therapy one nodule injection second nodule Dulbecco 's phosphate buffer saline . The next day , patient begin chemotherapy , may give weekly continue every 21-28 day 6 course . On day 3 , patient return biopsy injected nodule . Biopsies perform first course . Patients may receive injection Ad-p53 gene subsequent course chemotherapy , six course . Patients follow monthly 4 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm epithelial breast cancer At least 3 cutaneous subcutaneous lesion require Measurable disease include , limited , cutaneous subcutaneous metastasis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Absolute granulocyte count least 1,500/mm3 Hemoglobin great 8 g/dL Platelet count great 100,000/mm3 Bilirubin less 2 mg/dL PT/PTT within normal range SGOT/SGPT le 2 time upper limit normal Creatinine le 1.8 mg/dL Not pregnant Fertile patient must use effective contraception 3 month therapy PRIOR CONCURRENT THERAPY : Concurrent cytotoxic chemotherapy allow , stable respond At least 4 week since prior chemotherapy , start new regimen At least 4 week since radiotherapy Prior adjuvant radiotherapy chest wall allow At least 6 month since radiotherapy lesion inject Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2001</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>